Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Bullish +65

Fisher Funds Management LTD Sells 242,305 Shares of Edwards ...

AI-generated analysis

📉 Fisher Funds Management LTD sold 242,305 shares of Edwards Lifesciences in Q1, reducing its stake by 31.8% to 519,594 shares.

📈 Hsbc Holdings PLC increased its position by 0.7% to own 2.14 million shares valued at $183.19 million during the fourth quarter.

🏆 Wolfe Research upgraded Edwards Lifesciences to 'outperform' with a $92 price target, while Royal Bank of Canada set a $100 target.

💰 The company reported Q1 revenue of $1.65 billion, beating analyst estimates by $50 million and growing 16.7% year-over-year.

📊 Edwards Lifesciences posted earnings per share of $0.78, surpassing the consensus estimate of $0.73 with a 17.39% net margin.

🔮 Management guided FY 2026 EPS between $2.95 and $3.05, indicating continued growth expectations for the fiscal year.

📉 Insiders sold 81,038 shares valued at $6.68 million in the last quarter, with VP Donald Bobo reducing his stake by 19%.

💵 The stock trades at a P/E ratio of 46.55 with a market capitalization of $50.39 billion and a beta of 0.87.

🏥 Edwards Lifesciences focuses on structural heart disease therapies, including the SAPIEN family of transcatheter heart valves.

📉 The stock opened at $87.51, trading above its 50-day moving average of $83.39 but below its 200-day average of $83.13.

Bullish Signals
  • Edwards Lifesciences beat Q1 earnings estimates with EPS of $0.78 versus the consensus of $0.73, demonstrating strong operational performance.
  • Revenue reached $1.65 billion in the quarter, representing a significant 16.7% increase compared to the same period last year.
  • Multiple analysts have upgraded the stock or raised price targets, with Royal Bank of Canada setting a high $100 target and Wolfe Research issuing an 'outperform' rating.
  • The company maintains a very strong balance sheet with a current ratio of 4.42 and a negligible debt-to-equity ratio of 0.06.
  • Institutional investors like Hsbc Holdings PLC and Corient Private Wealth LLC increased their stakes, signaling continued confidence in the business model.
Risk Factors
  • Insiders sold a total of 81,038 shares valued at $6.68 million over the last quarter, indicating some internal profit-taking or portfolio rebalancing.
  • Fisher Funds Management LTD significantly reduced its position by 31.8% in Q1, selling 242,305 shares which may reflect a change in institutional sentiment.
Full Analysis
Fisher Funds Management LTD reduced its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 31.8% during the first quarter, selling 242,305 shares. The firm now holds 519,594 shares, valued at $41.6 million, representing 1.2% of its portfolio and ranking as the 25th largest holding. Despite this reduction, several other institutional investors increased their stakes in the fourth quarter, including Hsbc Holdings PLC, which raised its position by 0.7% to own over 2.14 million shares valued at $183.19 million. Analyst sentiment remains largely positive with multiple firms upgrading ratings or raising price targets. Wolfe Research upgraded the stock to 'outperform' with a $92 target, while Mizuho and Royal Bank of Canada also issued 'outperform' ratings with targets of $95 and $100 respectively. The consensus average price target stands at $95.96 based on 27 analysts, with the majority assigning Buy or Strong Buy ratings to the medical technology company. Financially, Edwards Lifesciences reported strong quarterly results with revenue of $1.65 billion, beating estimates by $50 million and showing a 16.7% year-over-year increase. The company posted earnings per share of $0.78 versus a consensus of $0.73, achieving a net margin of 17.39%. Management provided guidance for FY 2026 EPS between $2.95 and $3.05, with Q2 2026 expected to range from $0.70 to $0.76. Insider trading activity shows some selling pressure as SVP Andrew Dahl and VP Donald Bobo sold shares totaling over $2 million in May. Over the last quarter, insiders collectively sold 81,038 shares valued at approximately $6.68 million, though they still retain a small direct ownership stake of 0.31%. The company maintains a robust balance sheet with a current ratio of 4.42 and minimal debt-to-equity of 0.06.